Recently, pharmacologic studies have suggested that FGF21 improves cardiac function and alleviates Ang II-induced cardiac hypertrophy in a SIRT1-dependent manner (Li et al., 2019). This evidence concerns the gene SIRT1 and cardiac hypertrophy.